Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SAN ANTONIO, Texas, Jan. 05, 2018 -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced that it will present its proprietary technology to detect and treat multiple cancers at the cellular level at Biotech Showcase™ 2018, an annual investor conference for the biotech industry.
bioAffinity Technologies CEO Maria Zannes will present bioAffinity’s breakthrough platform that specifically and selectively targets cancer cells on Tuesday, Jan. 9, at 4:45 p.m. in the Yosemite Room at the Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference that gives private and public biotechnology and life sciences companies the opportunity to meet with investors and pharmaceutical executives at the J.P. Morgan Annual Healthcare Conference, one of the industry's largest annual healthcare investor conferences.
Sara Demy-Colton, CEO of Demy-Colton, said, “We are delighted that bioAffinity Technologies will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
